Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1670922 | 1.00 | HCRTR1 (0.51) | HCRTR1HCRTR2 | |
| SCHEMBL29117985 | 1.00 | HCRTR1 (0.51) | HCRTR1HCRTR2 | |
| Hydrochloric Acid SCHEMBL29367258 | 0.98 | HCRTR1 (0.50) | HCRTR1HCRTR2 | |
| Hydrochloric Acid SCHEMBL15796256 | 0.98 | HCRTR1 (0.50) | HCRTR1HCRTR2 | |
| SCHEMBL29118005 | 0.89 | ROCK2 (0.50) | HCRTR1HCRTR2 | |
| SCHEMBL29614755 | 0.89 | HCRTR1 (0.43) | HCRTR1HCRTR2 | |
| SCHEMBL27029902 | 0.89 | ROCK2 (0.50) | HCRTR1HCRTR2 | |
| SCHEMBL29118052 | 0.89 | ROCK2 (0.50) | HCRTR1HCRTR2 | |
| SCHEMBL29118006 | 0.89 | ROCK2 (0.50) | HCRTR1HCRTR2 | |
| SCHEMBL27029985 | 0.89 | ROCK2 (0.50) | HCRTR1HCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114555603-B | Improved synthetic methods for preparing (2H-1, 2, 3-triazol-2-yl) phenyl compounds as orexin receptor modulators | 詹森药业有限公司 | 2025-03-14 | — | — | CN | claimed |
| CN-113038952-B | Improved synthetic methods for preparing fused heterocyclic compounds as orexin receptor modulators | 詹森药业有限公司 | 2024-08-23 | — | — | CN | claimed |
| EP-3880204-B1 | IMPROVED SYNTHETIC METHODS OF MAKING FUSED HETEROCYCLIC COMPOUNDS AS OREXIN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2024-05-15 | — | — | EP | claimed |
| EP-4010325-A1 | IMPROVED SYNTHETIC METHODS OF MAKING (2H-1,2,3-TRIAZOL-2-YL)PHENYL COMPOUNDS AS OREXIN RECEPTOR MODULATORS | Janssen Pharmaceutica NV (BE) | 2022-06-15 | — | — | EP | claimed |
| CN-114555603-A | Improved synthesis for the preparation of (2H-1,2, 3-triazol-2-yl) phenyl compounds as orexin receptor modulators | 詹森药业有限公司 | 2022-05-27 | — | — | CN | claimed |
| CN-114555603-B | Improved synthetic methods for preparing (2H-1, 2, 3-triazol-2-yl) phenyl compounds as orexin receptor modulators | 詹森药业有限公司 | 2025-03-14 | — | — | CN | disclosed |
| EP-4428136-A2 | IMPROVED SYNTHETIC METHODS OF MAKING FUSED HETEROCYCLIC COMPOUNDS AS OREXIN RECEPTOR MODULATORS | Janssen Pharmaceutica N.V. (BE) | 2024-09-11 | — | — | EP | disclosed |
| CN-118556061-A | Disubstituted octahydropyrrolo [3,4-c ] pyrrole methyl ketone derivative and application thereof | 江苏恩华药业股份有限公司 | 2024-08-27 | — | — | CN | disclosed |
| CN-113038952-B | Improved synthetic methods for preparing fused heterocyclic compounds as orexin receptor modulators | 詹森药业有限公司 | 2024-08-23 | — | — | CN | disclosed |
| CN-113038952-B | Improved synthetic methods for preparing fused heterocyclic compounds as orexin receptor modulators | 詹森药业有限公司 | 2024-08-23 | — | — | CN | disclosed |
| US-12030887-B2 | Synthetic methods of making fused heterocyclic compounds as orexin receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2024-07-09 | — | — | US | disclosed |
| US-12030887-B2 | Synthetic methods of making fused heterocyclic compounds as orexin receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2024-07-09 | — | — | US | disclosed |
| EP-4310089-A1 | NITROGEN-CONTAINING HETEROCYCLIC POLYCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | Shanghai Hansoh Biomedical Co., Ltd. (CN) | 2024-01-24 | — | — | EP | disclosed |
| CN-116981670-A | Polycyclic compound containing nitrogen heterocycle, preparation method and application thereof | 上海翰森生物医药科技有限公司 | 2023-10-31 | — | — | CN | disclosed |
| EP-4010325-A1 | IMPROVED SYNTHETIC METHODS OF MAKING (2H-1,2,3-TRIAZOL-2-YL)PHENYL COMPOUNDS AS OREXIN RECEPTOR MODULATORS | Janssen Pharmaceutica NV (BE) | 2022-06-15 | — | — | EP | disclosed |
| CN-114555603-A | Improved synthesis for the preparation of (2H-1,2, 3-triazol-2-yl) phenyl compounds as orexin receptor modulators | 詹森药业有限公司 | 2022-05-27 | — | — | CN | disclosed |
| US-20220009932-A1 | IMPROVED SYNTHETIC METHODS OF MAKING FUSED HETEROCYCLIC COMPOUNDS AS OREXIN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2022-01-13 | — | — | US | disclosed |
| EP-3880204-A1 | IMPROVED SYNTHETIC METHODS OF MAKING FUSED HETEROCYCLIC COMPOUNDS AS OREXIN RECEPTOR MODULATORS | Janssen Pharmaceutica N.V. (BE) | 2021-09-22 | — | — | EP | disclosed |
| WO-2020100011-A1 | IMPROVED SYNTHETIC METHODS OF MAKING FUSED HETEROCYCLIC COMPOUNDS AS OREXIN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2020-05-22 | — | — | WO | disclosed |
| WO-2020100011-A1 | IMPROVED SYNTHETIC METHODS OF MAKING FUSED HETEROCYCLIC COMPOUNDS AS OREXIN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2020-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12030887-B2 | Synthetic methods of making fused heterocyclic compounds as orexin receptor modulators | HCRTR2, HCRTR1, HTR3D | HCRTR1 2/4885HCRTR2 1/4885 |
| US-20220009932-A1 | IMPROVED SYNTHETIC METHODS OF MAKING FUSED HETEROCYCLIC COMPOUNDS AS OREXIN RECEPTOR MODULATORS | HCRTR2, HCRTR1, HTR3D | HCRTR1 2/4885HCRTR2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.